Dark

AFMD
Affimed N.V.
stock NASDAQ

At Close

May 16, 2025 3:59:30 PM EDT

0.2751USD+223.267%(+0.1900)919,289,652

0.00Bid 0.00Ask 0.0000Spread

Pre-market

May 16, 2025 9:28:30 AM EDT

0.1820USD+113.866%(+0.0969)99,161,985

After-hours

May 16, 2025 4:58:30 PM EDT

0.2143USD-22.101%(-0.0608)7,252,614

OverviewOptionsHistoricalExchangesShortsNews

Jan 6, 2022

06:36AM EST Affimed Completes Enrollment Of REDIRECT Study; Sees Topline Clinical Readout In 2H 2022 RTTNews

06:30AM EST Affimed Announces Completion of Enrollment in REDIRECT, the GlobeNewswire Inc

Jan 5, 2022

06:30AM EST Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference onThursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time. GlobeNewswire Inc

Dec 13, 2021

09:05AM EST Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and GlobeNewswire Inc

Dec 9, 2021

06:30AM EST Affimed to Host Virtual Investor Call Today to Discuss Treatment GlobeNewswire Inc

Dec 8, 2021

06:38AM EST Affimed Initiates Patient Recruitment For Phase 1/2a Trial Of Innate Cell Engager AFM24 With Roche's Atezolizumab RTTNews

06:36AM EST Affimed Initiates Patient Recruitment For A Phase 1/2a Trial Of Innate Cell Engager AFM24 In Combination With Roche's Anti-PD-L1 Checkpoint Inhibitor Atezolizumab Benzinga

06:30AM EST Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of GlobeNewswire Inc

Nov 22, 2021

09:55AM EST Affimed shares were trading higher after the company reported a 100% response rate in its phase 1-2 study of lymphomas. Benzinga

07:16AM EST Affimed Announces 100% Objective Response Rate At Highest Dose In Phase 1-2 Study Of Cord Blood-derived Natural Killer Cells Pre-complexed With Innate Cell Engager AFM13 For CD30-positive Lymphomas Benzinga

07:12AM EST Affimed Announces 100% Objective Response Rate at Highest Dose in GlobeNewswire Inc

Nov 17, 2021

02:39PM EST Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher Benzinga

Nov 12, 2021

07:01AM EST Affimed Shares Preclinical Data on Mechanism of Action of two GlobeNewswire Inc

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

08:08AM EST Recap: Affimed Q3 Earnings Benzinga

06:42AM EST Affimed NV Reports Q3 2021 EPS (0.14) Down From (0.07) YoY, Sales 8.66M Down From 10.55M YoY Benzinga

06:30AM EST Affimed Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 9, 2021

06:30AM EST Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of November 2021. GlobeNewswire Inc

Nov 8, 2021

06:34AM EST Affimed And NKGen Biotech Announce Initiation Of Patient Recruitment In A First-in-human Phase 1/2a Trial Of Innate Cell Engager AFM24 In Combination With Autologous NK Cell Product SNK01 Benzinga

06:30AM EST Affimed and NKGen Biotech Announce Initiation of Patient GlobeNewswire Inc

Nov 4, 2021

09:28AM EDT Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 To Treat Acute Myeloid Leukemia Benzinga

Oct 29, 2021

06:30AM EDT Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 2021, and host a conference call at 8:30 a.m. EST to discuss financial results and recent corporate developments. GlobeNewswire Inc

Oct 21, 2021

12:12PM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2021 Benzinga

12:11PM EDT Truist Securities Initiates Coverage On Affimed with Buy Rating, Announces Price Target of $10 Benzinga

Oct 12, 2021

07:09AM EDT SVB Leerink Maintains Outperform on Affimed, Lowers Price Target to $12 Benzinga

Oct 1, 2021

08:17AM EDT Affimed Announces Acceptance Of Three Abstracts With Preclinical Data On Its Innate Cell Engagers At 36th Annual Meeting Of The Society For Immunotherapy Of Cancer Nov. 10-14 Benzinga

08:09AM EDT Affimed Announces Acceptance of Three Abstracts with Preclinical GlobeNewswire Inc

Sep 30, 2021

11:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 Benzinga

04:52AM EDT Stifel Initiates Coverage On Affimed with Buy Rating, Announces Price Target of $12 Benzinga

Sep 8, 2021

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

06:34AM EDT Affimed Reports Q2 Sales 9.7M Up From Benzinga

06:30AM EDT Affimed Reports Second Quarter 2021 Financial Results and GlobeNewswire Inc

04:04AM EDT Earnings Scheduled For September 8, 2021 Benzinga

Sep 5, 2021

01:14PM EDT The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week Benzinga

Aug 26, 2021

06:30AM EDT Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that management will present and host one-on-one meetings at the following investor conferences during the month of September 2021. GlobeNewswire Inc

Aug 23, 2021

06:30AM EDT Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments. GlobeNewswire Inc

Jul 30, 2021

06:30AM EDT Affimed Announces Publication of Comprehensive Preclinical Data GlobeNewswire Inc

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

06:38AM EDT Affimed Q1 Net Income EUR 1.4 Mln Or EUR 0.01/Shr Vs Loss Of EUR 8.3 Mln Or EUR 0.11/Shr Last Year RTTNews

06:37AM EDT Affimed Reports Q1 EPS 0.01 Up From (0.11) YoY, Sales 11.66M Up From 5.14M YoY Benzinga

06:30AM EDT Affimed Reports First Quarter 2021 Financial Results GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For July 1, 2021 Benzinga

Jun 30, 2021

12:00PM EDT Affimed Earnings Preview Benzinga

Jun 25, 2021

10:16AM EDT Affimed Option Alert: Jul 16 $10 Calls Sweep (20) near the Ask: 854 @ $0.35 vs 3682 OI; Earnings 8/10 Before Open [est] Ref=$8.53 Benzinga

Jun 22, 2021

06:30AM EDT Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release first quarter 2021 results on Thursday, July 1, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments. GlobeNewswire Inc

Jun 16, 2021

07:05AM EDT Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. GlobeNewswire Inc

May 26, 2021

06:30AM EDT Heidelberg, Germany, May 26, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:30 a.m. Eastern Time. GlobeNewswire Inc

May 20, 2021

04:30PM EDT Affimed Announces Virtual Annual General Meeting of Shareholders GlobeNewswire Inc

May 14, 2021

09:30AM EDT Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies Benzinga

May 13, 2021

04:15PM EDT Affimed Announces The Publication Of Its Preclinical Data In Clinical Cancer Research Supporting Therapeutic Potential Of AFM13 In Combination With Natural Killer Cells Benzinga

04:01PM EDT Affimed Announces Publication of Preclinical Data in Clinical GlobeNewswire Inc

Apr 27, 2021

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

Apr 16, 2021

12:31PM EDT Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger Benzinga

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

06:40AM EDT Affimed Reports FY20 EPS (0.50), Same YoY Benzinga

06:30AM EDT Affimed Reports 2020 Financial Results and Highlights Recent GlobeNewswire Inc

04:13AM EDT Earnings Scheduled For April 15, 2021 Benzinga

Apr 14, 2021

11:29AM EDT Ridgeback Capital Investments Reports In 13G Filing A 5.5% Stake In Affimed Benzinga

10:35AM EDT Preview: Affimed's Earnings Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 12, 2021

08:31AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, Apr. 12, 2021: NVDA, NIO, FCAC, AFMD, APP Benzinga

06:38AM EDT Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I Benzinga

06:30AM EDT -- AFM24 induces strong tumor cell killing independent of KRAS mutations -- AFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression GlobeNewswire Inc

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Apr 9, 2021

02:36PM EDT Mid-Afternoon Market Update: Dow Surges Over 100 Points; Provention Bio Shares Plunge Benzinga

12:13PM EDT Mid-Day Market Update: WD-40 Drops After Weak Q2 Results; Celcuity Shares Jump Benzinga

10:38AM EDT Mid-Morning Market Update: Markets Open Higher; US Producer Prices Rise 1% In March Benzinga

10:13AM EDT Shares of clinical-stage immuno-oncology company Affimed N.V. (AFMD) are up more than 20% Friday morning after the company announced positive initial data from the Phase 1 study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE), AFM13 in solid tumors. RTTNews

07:04AM EDT Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity Benzinga

06:01AM EDT Affimed Highlights Presentation Of Initial Data From Phase 1 Study Of Cord Blood-Derived Natural Killer Cells Pre-Complexed With Innate Cell Engager At American Association For Cancer Research Meeting Apr. 13 at 1:30 p.m. EDT Benzinga

05:59AM EDT Affimed Announces Presentation at AACR Highlighting Initial Data GlobeNewswire Inc

Apr 8, 2021

06:30AM EDT Heidelberg, Germany, April 8, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2020 results and corporate update on Thursday, April 15, 2021. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. GlobeNewswire Inc

Mar 31, 2021

10:14AM EDT Affimed To Study AFM24/SNK-01 Combo In Solid Tumor Settings Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

08:19AM EDT Credit Suisse Initiates Coverage On Affimed with Outperform Rating, Announces Price Target of $15 Benzinga

06:32AM EDT Affimed And NKMax America Announce FDA Clearance Of IND Application To Study Combination Of AFM24 With SNK-01 Natural Killer Cell Therapy In Solid Tumors Benzinga

06:30AM EDT Affimed and NKMax America Announce FDA Clearance of IND GlobeNewswire Inc

Mar 24, 2021

06:49AM EDT Wells Fargo Maintains Overweight on Affimed, Raises Price Target to $15 Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 17, 2021

07:43AM EDT The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes Benzinga

Mar 12, 2021

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

07:30AM EST SVB Leerink Maintains Outperform on Affimed, Raises Price Target to $14 Benzinga

Mar 10, 2021

05:22PM EST -- AFM24 preclinical in vivo data will be presented as a poster -- Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium GlobeNewswire Inc

08:26AM EST Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data Benzinga

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

06:44AM EST Affimed Announces Continuation Of REDIRECT Study Of AFM13 In PTCL Following Preplanned Interim Futility Analysis Benzinga

06:37AM EST Affimed To Continue Enrollment In REDIRECT Trial For Patients With Relapsed Or Refractory CD30-positive PTCL RTTNews

06:30AM EST -- Study will continue and combine cohorts of CD30 high and CD30 low expressing PTCL based on assessment from Independent Review Committee -- Objective responses observed in heavily pretreated patients in both cohorts -- Side effect profile similar to previously reported data -- Conference call scheduled for March 10th at 8:30 a.m. EST GlobeNewswire Inc

Feb 8, 2021

05:29PM EST Affimed 13G Filing From Point72 Shows Raised Stake From 2M Shares To ~5.8M Shares, Or 5% Stake In Co. Benzinga

Feb 3, 2021

08:43AM EST Affimed Partners With Roche To Develop AFM24 Combo Therapy In EGFR Expressing Solid Tumors Benzinga

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

06:36AM EST Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors Benzinga

06:30AM EST Affimed Announces Collaboration with Roche to Study AFM24 in GlobeNewswire Inc

Jan 15, 2021

09:22AM EST Affimed Announces Closing of Public Offering of Common Shares and GlobeNewswire Inc

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

06:15AM EST Affimed Prices ~16.667M Share Offering At $6/Share Benzinga

06:15AM EST Affimed Announces Pricing of $100,000,000 Public Offering of GlobeNewswire Inc

06:00AM EST Hearing Affimed 10M Share Offering Priced @$6/Share Benzinga

Jan 12, 2021

04:02PM EST Affimed Announced A Common Stock Offering; No Terms Disclosed Benzinga

04:01PM EST Affimed Announces Proposed Public Offering of Common Shares GlobeNewswire Inc

Jan 11, 2021

06:45AM EST Heidelberg, Germany, January 11, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 7:30 a.m. Eastern Standard Time. GlobeNewswire Inc

06:31AM EST Affimed Announces 25 Million Debt Financing Agreement with Silicon Valley Bank Benzinga

06:30AM EST -- 10 million available at closing and up to 15 million available upon achievement of certain milestones GlobeNewswire Inc

Jan 7, 2021

06:30AM EST -- Continued progress for AFM13 and AFM24 clinical studies -- Strengthened cash position provides anticipated runway into the first half of 2023 GlobeNewswire Inc

Dec 23, 2020

04:17PM EST Affimed F-3 Shows Registration For $225M Mixed Securities Offering Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

10:16AM EST Affimed Announces Updated AFM13 Clinical Data Presentation At American Society of Hematology Annual Meeting, Demonstrating Good Tolerability And High Objective Response Rate In Patients With Recurrent/Refractory CD30-positive Lymphoma Benzinga

10:12AM EST Affimed Says AFM13 Monotherapy Was Well Tolerated And Reached An Objective Response Rate RTTNews

10:01AM EST -- AFM13 monotherapy was well tolerated and reached an Objective Response Rate of 42 percent among heavily pretreated patients with R/R CD30-positive lymphoma with cutaneous presentation -- Immunological analyses revealed that innate cell engagers modulate NK and T cell populations in peripheral blood and tumors GlobeNewswire Inc

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

04:02PM EST Affirmed Announces Publication Of Final Study Results Of Its Innate Cell Engager Candidate AFM13 In Combination With MSD's Anti-PD-1 Therapy KETRUDA In Blood Benzinga

04:01PM EST Affimed Announces Publication of Final Study Results of its Innate GlobeNewswire Inc

Nov 11, 2020

04:14AM EST SVB Leerink Maintains Outperform on Affimed, Raises Price Target to $9 Benzinga

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

07:35AM EST Affimed: Q3 Earnings Insights Benzinga

06:30AM EST Affimed Reports Third Quarter 2020 Financial Results and GlobeNewswire Inc

Nov 9, 2020

04:11PM EST Affimed And Roivant Sciences Announce Licensing And Strategic Collaboration Agreement To Develop And Commercialize Novel Innate Cell Engagers (ICE) For Multiple Cancer Targets, Affimed Will Receive $60M In Upfront Consideration Benzinga

04:01PM EST Affimed and Roivant Sciences Announce Licensing and Strategic GlobeNewswire Inc

10:18AM EST Affimed Earnings Preview Benzinga

08:34AM EST Affimed NV Reports New Preclinical Data Being Presented At SITC Underscore Promising Combinations Of Co's AFM13, Cytokine-Activated Natural Killer Cells Benzinga

08:20AM EST New Preclinical Data being Presented at SITC Underscore Promising GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 4, 2020

04:39PM EST Affimed Announces Presentations On Its AFM13 Innate Cell Engager At The 62nd American Society Of Hematology Annual Meeting And Exposition Dec. 6-7 Benzinga

04:05PM EST Affimed Announces Presentations on its AFM13 Innate Cell Engager GlobeNewswire Inc

06:30AM EST Heidelberg, Germany, November 4, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the companys management will participate in the following investor conferences during the month of November: GlobeNewswire Inc

Nov 3, 2020

06:30AM EST Heidelberg, Germany, November 3, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2020 results on Tuesday, November 10, 2020 and host a conference call at 8:30 a.m. ET to discuss financial results and corporate developments. GlobeNewswire Inc

Oct 20, 2020

06:38AM EDT Affimed And NKMax America To Study The Combination of AFM24, An EGFR-Targeted Innate Cell Engager, With SNK01 Natural Killer Cell Therapy Benzinga

06:30AM EDT -- Proof of Concept study to establish safety and recommended dose of Affimeds innate cell engager (ICE) AFM24 in combination with NKMax Americas Natural Killer (NK) cells in solid tumors -- Pre-clinical data substantiates synergy between Affimeds ICE molecules and both NKMax Americas autologous and cryopreserved allogeneic NK cell therapy products GlobeNewswire Inc

Oct 14, 2020

05:15PM EDT Affimed Announces Presentation of Preclinical Data on GlobeNewswire Inc

Oct 6, 2020

06:35AM EDT Affimed Doses First Patient In Phase 1 Clinical Trial Of Cord Blood-derived Natural Killer Cells With AFM13 RTTNews

06:32AM EDT Affimed Announces Dosing Of First Patient In Phase 1 Clinical Trial Of Cord Blood-Derived Natural Killer Cells In Combination With The Innate Cell Engager AFM13 Benzinga

06:30AM EDT AbCheck s.r.o. Receives Grant to Further Develop a Discovery GlobeNewswire Inc

06:30AM EDT Affimed Announces Dosing of First Patient in Phase 1 Clinical GlobeNewswire Inc

Sep 29, 2020

06:30AM EDT Heidelberg, Germany, September 29, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the companys management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time. GlobeNewswire Inc

Sep 2, 2020

06:30AM EDT Affimed to Present at Upcoming Investor Conferences GlobeNewswire Inc

Aug 11, 2020

07:29AM EDT Affimed: Q2 Earnings Insights Benzinga

06:42AM EDT Affimed Q2 Net Loss EUR 12.2 Mln Or EUR 0.16 Per Share RTTNews

06:37AM EDT Affimed Q2 EPS (0.16) Benzinga

06:30AM EDT Affimed Reports Second Quarter 2020 Financial Results and GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 11, 2020 Benzinga

Aug 10, 2020

10:57AM EDT Earnings Outlook For Affimed Benzinga

Aug 5, 2020

06:44AM EDT Affimed Appoints Annalisa Jenkins And Harry Welten To Its Supervisory Board RTTNews

06:30AM EDT Affimed Announces Two New Appointments to Its Supervisory Board GlobeNewswire Inc

Aug 4, 2020

06:30AM EDT Heidelberg, Germany, August 4, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2020 results on Tuesday, August 11, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and corporate developments. GlobeNewswire Inc

.dark-mode .Bqyk4H{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .Bqyk4H{ color: #333333; background-color: white; border: 2px solid #333333; }AFMDAffimed N.V.stock NASDAQ

AFMD
Affimed N.V.
stock NASDAQ